150 related articles for article (PubMed ID: 32199750)
1. Lipidomics-based assays coupled with computational approaches can identify novel phospholipase A
Mouchlis VD; Mu C; Hammons R; Dennis EA
Adv Biol Regul; 2020 May; 76():100719. PubMed ID: 32199750
[TBL] [Abstract][Full Text] [Related]
2. Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and Structure-Activity Relationships.
Mouchlis VD; Limnios D; Kokotou MG; Barbayianni E; Kokotos G; McCammon JA; Dennis EA
J Med Chem; 2016 May; 59(9):4403-14. PubMed ID: 27087127
[TBL] [Abstract][Full Text] [Related]
3. Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A
Mouchlis VD; Morisseau C; Hammock BD; Li S; McCammon JA; Dennis EA
Bioorg Med Chem; 2016 Oct; 24(20):4801-4811. PubMed ID: 27320659
[TBL] [Abstract][Full Text] [Related]
4. Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2).
Chinnasamy S; Selvaraj G; Selvaraj C; Kaushik AC; Kaliamurthi S; Khan A; Singh SK; Wei DQ
Int J Biol Macromol; 2020 Feb; 144():53-66. PubMed ID: 31838071
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics simulations reveal structural insights into inhibitor binding modes and functionality in human Group IIA phospholipase A
Kim RR; Malde AK; Nematollahi A; Scott KF; Church WB
Proteins; 2017 May; 85(5):827-842. PubMed ID: 28056488
[TBL] [Abstract][Full Text] [Related]
6. Structures and binding studies of the complexes of phospholipase A2 with five inhibitors.
Shukla PK; Gautam L; Sinha M; Kaur P; Sharma S; Singh TP
Biochim Biophys Acta; 2015 Apr; 1854(4):269-77. PubMed ID: 25541253
[TBL] [Abstract][Full Text] [Related]
7. Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases.
Yarla NS; Bishayee A; Vadlakonda L; Chintala R; Duddukuri GR; Reddanna P; Dowluru KS
Curr Drug Targets; 2016; 17(16):1940-1962. PubMed ID: 26212262
[TBL] [Abstract][Full Text] [Related]
8. High-affinity selective inhibitor against phospholipase A2 (PLA2): a computational study.
Chinnasamy S; Chinnasamy S; Muthusamy K
J Recept Signal Transduct Res; 2016; 36(2):111-8. PubMed ID: 26422703
[TBL] [Abstract][Full Text] [Related]
9. Virtual analysis of structurally diverse synthetic analogs as inhibitors of snake venom secretory phospholipase A2.
Sivaramakrishnan V; Ilamathi M; Ghosh KS; Sathish S; Gowda TV; Vishwanath BS; Rangappa KS; Dhananjaya BL
J Mol Recognit; 2016 Jan; 29(1):22-32. PubMed ID: 26218369
[TBL] [Abstract][Full Text] [Related]
10. Phospholipase A
Mouchlis VD; Dennis EA
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Jun; 1864(6):766-771. PubMed ID: 30905345
[TBL] [Abstract][Full Text] [Related]
11. Substrate-Specific Inhibition Constants for Phospholipase A
Mouchlis VD; Armando A; Dennis EA
J Med Chem; 2019 Feb; 62(4):1999-2007. PubMed ID: 30615445
[TBL] [Abstract][Full Text] [Related]
12. Sulfur Compounds as Inhibitors of Enzymatic Activity of a Snake Venom Phospholipase A
Henao Castañeda I; Pereañez JA; Preciado LM; Jios J
Molecules; 2020 Mar; 25(6):. PubMed ID: 32197309
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of bioactive compounds of Clematis gouriana Roxb. ex DC against snake venom phospholipase A
Muthusamy K; Chinnasamy S; Nagarajan S; Sivaraman T; Chinnasamy S
J Biomol Struct Dyn; 2017 Jul; 35(9):1936-1949. PubMed ID: 27355444
[TBL] [Abstract][Full Text] [Related]
14. A systematic methodology for large scale compound screening: A case study on the discovery of novel S1PL inhibitors.
Deniz U; Ozkirimli E; Ulgen KO
J Mol Graph Model; 2016 Jan; 63():110-24. PubMed ID: 26724452
[TBL] [Abstract][Full Text] [Related]
15. Lipoquality control by phospholipase A
Murakami M
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(9):677-702. PubMed ID: 29129849
[TBL] [Abstract][Full Text] [Related]
16. Targeting human secretory phospholipase A2 with designed peptide inhibitors for inflammatory therapy.
Wang P; Li Y; Shao Q; Zhou W; Wang K
J Drug Target; 2015 Feb; 23(2):140-6. PubMed ID: 25237841
[TBL] [Abstract][Full Text] [Related]
17. In Silico and In Vitro Study of the Bromelain-Phytochemical Complex Inhibition of Phospholipase A2 (Pla2).
Mohamed Tap F; Abd Majid FA; Ismail HF; Wong TS; Shameli K; Miyake M; Ahmad Khairudin NB
Molecules; 2018 Jan; 23(1):. PubMed ID: 29351216
[TBL] [Abstract][Full Text] [Related]
18. Structure-based grafting, mutation, and optimization of peptide inhibitors to fit in the active pocket of human secreted phospholipase A2: find new use of old Peptide agents with anti-inflammatory activity.
Zhan C; Li S; Zhong Q; Zhou D
Chem Biol Drug Des; 2015 Apr; 85(4):418-26. PubMed ID: 25187416
[TBL] [Abstract][Full Text] [Related]
19. Computational and in vitro insights on snake venom phospholipase A
Muthusamy K; Chinnasamy S; Nagarajan S; Sivaraman T
J Biomol Struct Dyn; 2018 Dec; 36(16):4197-4208. PubMed ID: 29171346
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel pyrazole series of group X secreted phospholipase A2 inhibitor (sPLA2X) via fragment based virtual screening.
Chen H; Knerr L; Åkerud T; Hallberg K; Öster L; Rohman M; Österlund K; Beisel HG; Olsson T; Brengdhal J; Sandmark J; Bodin C
Bioorg Med Chem Lett; 2014 Nov; 24(22):5251-5. PubMed ID: 25316315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
